Korlym

Drug Overview

In the complex field of Endocrinology, managing the overproduction of specific hormones is as critical as replacing those that are deficient. Korlym represents a specialized pharmacological advancement for patients struggling with the metabolic consequences of excessive cortisol. Classified as a Cortisol Receptor Blocker, Korlym provides a vital therapeutic pathway for individuals whose bodies are overwhelmed by “the stress hormone,” leading to severe systemic imbalances.

Unlike traditional treatments that aim to stop the production of hormones at the source, Korlym acts as a shield, protecting the body’s tissues from the harmful effects of hormone excess. It is a key component in the management of metabolic dysfunction when primary surgical interventions are not an option or have proven unsuccessful.

• Generic Name: Mifepristone
• US Brand Names: Korlym
• Drug Class: Cortisol Receptor Blocker (Glucocorticoid Receptor Antagonist)
• Route of Administration: Oral (Tablet)
• FDA Approval Status: FDA-approved (2012) for specific metabolic indications related to endogenous Cushing’s syndrome.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Korlym functions, one must examine the Hypothalamic-Pituitary-Adrenal (HPA) Axis. In a healthy state, cortisol regulates glucose metabolism, blood pressure, and immune response. In Cushing’s syndrome, cortisol levels remain pathologically high, leading to “steroid-induced” diabetes and significant weight gain.

Korlym utilizes a unique mechanism of Competitive Antagonism. Most Cushing’s medications work by inhibiting enzymes in the adrenal glands to stop cortisol production. Korlym, however, does not lower the amount of cortisol in the blood. In fact, cortisol levels often remain high or even increase during treatment. Instead, the medication travels to the glucocorticoid receptors (GR) located on cells throughout the body.

At the molecular level, Korlym binds to these receptors with high affinity—essentially “plugging the lock” so that the actual cortisol molecules cannot attach. By blocking the receptor, Korlym prevents cortisol from signaling the liver to produce excess glucose and stops it from breaking down muscle tissue for fuel. This blockade directly targets the root cause of hyperglycemia (high blood sugar) in these patients, allowing metabolic markers to stabilize even while the underlying hormonal overproduction persists. Additionally, Korlym acts as a Targeted Therapy by also blocking progesterone receptors, which is a secondary effect that requires careful clinical monitoring.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for Korlym is the control of hyperglycemia (high blood sugar) secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have Type 2 Diabetes Mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Other Approved & Off-Label Uses

While the primary focus is glucose management, the systemic blockade of cortisol has broader implications for Hormone Replacement Therapy balance and metabolic health:

• Primary Endocrinology Indications:
  • Management of insulin resistance associated with excess glucocorticoid activity.
  • Reduction of clinical symptoms of Cushing’s, such as central obesity and skin thinning, through receptor blockade.
  • Improvement of metabolic markers (blood pressure and weight) in the context of hypercortisolism.
• Off-Label/Research Uses:
  • Investigation into the treatment of refractory depression with psychotic features (linked to HPA axis dysregulation).
  • Potential use in certain Endocrine Malignancies that are fueled by glucocorticoid signaling.

Dosage and Administration Protocols

Korlym requires a precise titration schedule to ensure the body adjusts to the receptor blockade without triggering adrenal insufficiency-like symptoms.

Specialized Administration Details:

• Timing: The tablet must be taken once daily with a meal. This is crucial for consistent absorption and to minimize gastrointestinal discomfort.
• Renal Impairment: Maximum dose is typically limited to 600 mg daily in patients with mild-to-moderate renal impairment.
• Hepatic Impairment: For patients with moderate hepatic impairment, the dose should not exceed 600 mg per day. It is not recommended for severe hepatic failure.
• Drug Interactions: Korlym is a potent inhibitor of CYP3A enzymes; many common medications (like certain statins or blood thinners) require significant dose adjustments when taken concurrently.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Clinical efficacy for Korlym was primarily established through the SEISMIC study and continued through real-world data collection from 2020 to 2026. Because Korlym targets the receptor rather than the hormone level, efficacy is measured by biochemical and clinical “targets” rather than a drop in serum cortisol.

Research results indicated that 60% of patients with Type 2 Diabetes or glucose intolerance experienced a significant improvement in their glucose control. Precise numerical data showed a mean reduction in HbA1c percentage of 1.1% over a 24-week period. Furthermore, patients demonstrated a mean weight loss of approximately 5% of their total body weight, with some patients losing significantly more as the metabolic “brakes” were removed from their adipose tissue.

Recent studies (2023-2025) have also focused on blood pressure targets. Approximately 38% of patients in clinical cohorts achieved at least a 5 mmHg reduction in diastolic blood pressure. These results highlight that blocking the glucocorticoid receptor provides a comprehensive metabolic “reset” for patients who have exhausted surgical options.

Safety Profile and Side Effects

BLACK BOX WARNING: Korlym has a potent anti-progestational effect and will result in the termination of a pregnancy. Pregnancy must be excluded before the start of treatment and prevented during treatment. It is contraindicated in women who are pregnant or seeking to become pregnant.

Common Side Effects (>10%)

• Nausea and vomiting.
• Fatigue and dizziness.
• Arthralgia (joint pain).
• Hypokalemia (low potassium levels).
• Endometrial thickening (in women, due to progesterone blockade).

Serious Adverse Events

• Adrenal Insufficiency: Even though cortisol levels are high, the receptors are blocked, which can lead to “functional” adrenal crisis (nausea, hypotension, extreme weakness).
• Severe Hypokalemia: Can lead to cardiac arrhythmias; requires aggressive potassium supplementation.
• Vaginal Bleeding: Due to endometrial changes.
• QT Prolongation: Potential for heart rhythm disturbances.

Management Strategies: Patients must undergo regular baseline electrolyte panels. Management of “functional” adrenal insufficiency often requires pausing the medication and using temporary Hormone Replacement Therapy (dexamethasone) that can overcome the blockade in emergencies.

Research Areas

Direct Clinical Connections: Current research (2024-2026) is investigating the drug’s interaction with the Hypothalamic-Pituitary-Adrenal (HPA) axis to determine if long-term receptor blockade leads to a permanent “re-setting” of the feedback loop. There is also specific research into Pancreatic Beta-cell Preservation, exploring whether blocking cortisol allows beta cells to recover from the “glucose toxicity” inherent in Cushing’s syndrome.

Generalization: Significant advancements are being made in Novel Delivery Systems, including the development of second-generation selective glucocorticoid receptor modulators (SGRMs) that do not block the progesterone receptor, potentially eliminating the risk of endometrial thickening and vaginal bleeding.

Severe Disease & Prevention: Extensive longitudinal studies are evaluating the drug’s efficacy in preventing long-term macrovascular complications (heart attack and stroke) by aggressively managing the metabolic syndrome that defines untreated Cushing’s.

Disclaimer: The research areas discussed for mifepristone (Korlym), including its potential effects on HPA axis modulation, pancreatic beta-cell preservation, and development of next-generation receptor modulators, are based on ongoing and exploratory studies. These findings are not yet fully established in clinical practice and should not be considered applicable to routine medical or professional treatment scenarios. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: HbA1c levels, fasting plasma glucose, and 24-hour urinary free cortisol (to confirm Cushing’s diagnosis).
• Organ Function: Hepatic monitoring (ALT/AST) and Renal function (eGFR).
• Specialized Testing: Pregnancy test (mandatory for women of childbearing age) and baseline electrolyte panels (Potassium).
• Screening: Baseline pelvic ultrasound for women to monitor endometrial thickness.

Monitoring and Precautions

• Vigilance: Monitoring for “therapeutic escape” is not common, but patients must be watched for signs of adrenal insufficiency even if their blood cortisol looks high.
• Lifestyle: Medical Nutrition Therapy (MNT) is essential, focusing on low-sodium and high-potassium intake. Weight-bearing exercise is encouraged to combat the osteoporosis often seen in Cushing’s.
• “Do’s and Don’ts” list:
  • DO carry a medical alert card stating you are on a cortisol receptor blocker.
  • DO notify your doctor immediately of any unexplained vaginal bleeding.
  • DON’T take Korlym with grapefruit juice, as it increases drug levels to dangerous heights.
  • DON’T stop the medication abruptly without medical guidance.

Legal Disclaimer

The medical information provided in this guide is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Korlym is a highly specialized medication that must be administered under the strict supervision of a board-certified Endocrinologist. Always consult with your healthcare provider regarding your specific condition and any potential drug interactions. Use of this medication in women of childbearing age requires strict adherence to pregnancy prevention protocols.